Atreo Hits 100 Studies, Signaling a Break from Legacy Clinical Tech

SAN FRANCISCO, CA – May 05, 2026 – By Tyler Nguyen

Atreo, a technology firm specializing in Randomization and Trial Supply Management (RTSM), announced today the launch of its 100th clinical study, a significant milestone that underscores a growing shift in the pharmaceutical and biotech industries. While the number itself is notable for a company founded in 2021, it’s the accompanying claim of 100% client retention that suggests a deeper disruption is underway, challenging the long-standing dominance of slower, more rigid legacy systems in clinical trial management.

As drug development becomes increasingly complex with adaptive trials and precision medicine, sponsors are growing impatient with technology that creates bottlenecks. Atreo's rapid growth, with a projection of over 70 new study launches in 2026 alone, indicates that its message of agility and speed is resonating with a market hungry for innovation. The company's success points to a fundamental change in expectations, where speed, flexibility, and expert service are no longer considered optional add-ons but core requirements.

"Reaching 100 studies in such a short period is more than a milestone—it is validation of our vision," said Ryan Harrison, Co-founder & CEO of Atreo, in the company's official announcement. "We founded Atreo with the belief that the limitations of legacy IRT could be solved through continuous platform innovation, thoughtful design, and a modern delivery model."

The Burden of Legacy Systems

For decades, clinical trials have been managed using Interactive Response Technology (IRT), the precursor to modern RTSM. However, many of these foundational systems, now considered 'legacy,' were built for a different era of drug development. They are often characterized by their rigidity, requiring extensive custom coding for each new study. This architecture creates significant challenges in today's fast-paced research environment.

Industry analyses reveal that building, validating, and deploying a study on a legacy IRT platform can take anywhere from six to twelve weeks. This initial delay is compounded whenever a trial protocol needs to be amended. Mid-study changes—a common occurrence in modern research—can trigger a cascade of costly and time-consuming processes, including contract revisions, custom recoding, and full system revalidation, often pushing timelines back by weeks or even months.

Furthermore, these older systems frequently operate in silos, failing to integrate seamlessly with other critical platforms like Electronic Data Capture (EDC) or Clinical Trial Management Systems (CTMS). This fragmentation leads to manual data reconciliation, increases the risk of errors, and provides a fragmented view of trial operations. A 2018 industry study highlighted these frustrations, with over 70% of clinical trial professionals citing challenges with mid-study changes and 74% pointing to a lack of integration as a major pain point. This technological friction ultimately translates into slower patient enrollment, potential drug wastage, and delayed market access for new therapies.

A New Blueprint for Agility

Atreo and a new wave of 'next-generation' RTSM providers are positioning themselves as the solution to these legacy woes. Their core value proposition rests on replacing custom coding with highly configurable platforms. Atreo, for its part, claims its system is "100% configurable," enabling it to build and deploy complex study designs in one to two weeks—a fraction of the time required by traditional providers.

This configurability is particularly crucial for managing mid-study changes. Where legacy systems require extensive redevelopment, Atreo asserts it can deliver system updates in days rather than months, often with no additional contracting or change fees. This agility allows sponsors to embrace more innovative and adaptive trial designs, which can lead to more efficient, targeted, and successful clinical outcomes. By adopting a "product-first" approach with multiple platform updates per year, the company aims to keep its technology ahead of evolving client needs, a stark contrast to the static nature of many older systems.

This modern approach has tangible benefits. Industry data suggests that optimized RTSM can reduce drug supply waste by 15-30% and cut overall trial durations by several weeks. By automating randomization, streamlining supply chain logistics, and enabling rapid protocol amendments, these next-generation platforms help minimize the operational friction that has long plagued clinical research, allowing sponsors to focus less on process and more on patient progress.

The Power of 100% Retention

Perhaps the most telling metric in Atreo's announcement is its 100% client retention rate. In the competitive B2B software market, particularly one serving the high-stakes pharmaceutical industry, achieving perfect retention across a client base that includes global pharma giants, emerging biotechs, and Contract Research Organizations (CROs) is a powerful validation of both product and service.

"Our client base spans large global pharmaceutical companies, emerging biotechs, CROs, and organizations of all sizes in between, all of whom are repeat customers," stated Keaton Fonvielle, Atreo's Head of Client Services. "That level of retention reflects the trust we have earned through consistent execution, strong partnership, and a highly consultative service model."

This success appears to stem from a deliberate strategy that combines technology with human expertise. Atreo emphasizes that its clients are supported "by RTSM experts only and always." This 'experts-only' model ensures that when study teams need support, they are engaging with professionals who have deep domain knowledge, eliminating the frustrating, multi-tiered support queues common with larger vendors. This consultative approach, where the vendor acts as a strategic partner rather than a mere software provider, builds the trust and reliability essential for long-term relationships.

Fueling Growth with a Clear Vision

Atreo's market traction is backed by a solid financial and strategic foundation. The company has raised $5.75 million in funding, with a Series A round led by what it describes as "RTSM Veterans and SaaS Visionaries," including Slack co-founders Stewart Butterfield and Cal Henderson. This backing from both industry insiders and tech luminaries lends significant credibility to its mission.

By successfully launching 100 studies and forecasting over 70 more in the current year, Atreo is demonstrating a scalable model that is capturing market share from established competitors like Medidata, Veeva, and Oracle Health Sciences. While still a smaller player compared to these behemoths, its lean team and focused execution appear to be a competitive advantage, enabling the nimbleness its platform champions.

The company's momentum reflects a broader industry trend where efficiency and speed are paramount. As the cost and complexity of drug development continue to rise, the tools used to manage that process are under intense scrutiny. The ability to accelerate a study from protocol approval to first patient in, and to adapt quickly to new data, can translate directly into a competitive advantage and, more importantly, faster access to potentially life-saving treatments for patients. Atreo's journey suggests that for a growing number of clinical trial sponsors, the era of accepting technological limitations as a cost of doing business is decisively coming to an end.